Olive Leaf Extract
A botanical that survived a head-to-head with captopril once, and awaits a second serious test.
C+
Evidence grade
C
Worth it
$12-22/month
Typical cost
DoseTrials used 500 mg of extract twice daily (standardized to oleuropein, commonly 20 percent) for blood pressure, and about 50 mg of oleuropein daily in the metabolic crossover. Olive leaf tea delivers far less. Products vary in standardization; the oleuropein percentage is the number to read.
BasisOlive leaf has what most botanicals in this tier lack: a randomized comparison against a real drug that did not embarrass it, plus a tidy metabolic crossover.
Olive leaf extract concentrates oleuropein, the bitter polyphenol of the olive tree, sold for blood pressure and metabolic support. We grade Olive Leaf Extract C+ on evidence and C for worth-it at about $12-22 per month.
What it does
Olive leaf extract concentrates oleuropein, the bitter polyphenol of the olive tree, sold for blood pressure and metabolic support. It borrows halo from the Mediterranean diet and the olive oil literature, which are different exposures; this record grades the leaf extract on its own trials.
What the research says
Lowers blood pressure comparably to a starter dose of captopril in one active-comparator trial
Evidence: emerging. Susalit 2011 randomized 232 adults with stage-1 hypertension to olive leaf extract (500 mg twice daily) or captopril (12.5 to 25 mg twice daily) for eight weeks: pressures fell about -11.5/-4.8 on the extract versus -13.7/-6.4 on the drug, a statistically comparable result. It is the best trial in this record and it is one trial, manufacturer-funded, without a placebo arm, so it cannot separate the extract from regression and context effects as cleanly as its headline suggests.
Improved insulin sensitivity in a small crossover trial in overweight men
Evidence: emerging. de Bock 2013: 46 overweight middle-aged men took olive leaf extract or placebo for 12 weeks in crossover; insulin sensitivity improved about 15 percent and beta-cell responsiveness about 28 percent. Small, single, and mechanistically interesting, with small lipid improvements reported in related work.
Olive leaf has what most botanicals in this tier lack: a randomized comparison against a real drug that did not embarrass it, plus a tidy metabolic crossover. What it lacks is everything around those two results: replication, placebo control in the flagship trial, long-term data, and independent research groups. C+ for a better-than-typical botanical file that still rests on two studies.
Is it worth it?
Evidence (C+) sits below the leaderboard floor, so the worth-it grade is capped at C+ however inexpensive it is; the derived value lands at C. About $17 a month at studied doses. Derived from the October 2026 worth-it model.
Typical cost
$12-22/month
Common form, not a brand recommendation
Dosage context established
Trials used 500 mg of extract twice daily (standardized to oleuropein, commonly 20 percent) for blood pressure, and about 50 mg of oleuropein daily in the metabolic crossover. Olive leaf tea delivers far less. Products vary in standardization; the oleuropein percentage is the number to read.
Worth-it leaderboard
Olive Leaf Extract sits outside the worth-it top 20.
Olive Leaf Extract sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Well tolerated in trials; mild GI effects and headache are reported. Blood-pressure and glucose effects are additive in principle with medication for either, so people on antihypertensives or diabetes drugs should treat it as an active product, not a garnish. Pregnancy data are absent.
Longevity Lab Report
Olive Leaf Extract news. Graded when it happens.
The grade on this page stays free. The email carries the news on olive leaf extract: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the Susalit active-comparator hypertension trial, the de Bock metabolic crossover, and the surrounding small-trial literature. The record credits the captopril comparison as the strongest single result while printing its design limits beside it.
- 2026-10-23|Listed under heart, matching this record's graded blood pressure findings.
The week's longevity and biohacking news.
This grade for Olive Leaf Extract rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.